Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | NQO2 | P16083 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407261 | 0.79 | MAPT (0.40) | MAPTNQO2KDM4EALDH1A1GAA | |
| SCHEMBL410281 | 0.71 | MAPT (0.46) | MAPTNQO2KDM4EALDH1A1GAA | |
| SCHEMBL577635 | 0.71 | HDAC6 (0.46) | MAPTKDM4EALDH1A1AKT1AKT2 | |
| SCHEMBL9479447 | 0.71 | MAPT (0.36) | MAPTNQO2KDM4EALDH1A1GAA | |
| SCHEMBL9480318 | 0.69 | MAPT (0.48) | MAPTNQO2KDM4EALDH1A1GAA | |
| SCHEMBL8916440 | 0.68 | MAPT (0.41) | MAPTNQO2KDM4EALDH1A1GAA | |
| SCHEMBL12132910 | 0.67 | MAPT (0.53) | MAPTNQO2KDM4EALDH1A1GAA | |
| SCHEMBL315192 | 0.67 | MAPT (0.46) | MAPTNQO2KDM4EALDH1A1GAA | |
| SCHEMBL9479792 | 0.67 | MAPT (0.46) | MAPTNQO2KDM4EALDH1A1GAA | |
| SCHEMBL558407 | 0.67 | TDP1 (0.50) | MAPTNQO2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735577-B2 | 1,3,5-triazine derivative, process for producing same, and organic electroluminescent element comprising same as constituent component | TOSOH CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2351750-B1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME AS CONSTITUENT | TOSOH CORP (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20110190494-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | TOSOH CORPORATION (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2351750-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | Tosoh Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190494-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | ASH2L, SETDB1, KAT5 | MAPT 2757/4885NQO2 2438/4885KDM4E 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.